Livzon Pharmaceutical Group (SZSE:000513) Net Income From Continuing Operations : ¥2,000 Mil (TTM As of Mar. 2024)

View and export this data going back to 1993. Start your Free Trial

What is Livzon Pharmaceutical Group Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Livzon Pharmaceutical Group's net income from continuing operations for the three months ended in Mar. 2024 was ¥716 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was ¥2,000 Mil.

Livzon Pharmaceutical Group Net Income From Continuing Operations Historical Data

The historical data trend for Livzon Pharmaceutical Group's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Livzon Pharmaceutical Group Net Income From Continuing Operations Chart

Livzon Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

1,461.58

2,131.33

1,952.10

1,955.58

1,897.60

Livzon Pharmaceutical Group Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															613.86	560.21	450.25	273.28	716.08

Livzon Pharmaceutical Group Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,000 Mil.

Livzon Pharmaceutical Group (SZSE:000513) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Livzon Pharmaceutical Group Inc (SZSE:000513) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

01513:Hong Kong LP6:Germany

Address

38 Chuangye North Road, Headquarters Building, Jinwan District, Guangdong Province, Zhuhai, CHN, 519090

Website

https://www.livzon.com.cn

Livzon Pharmaceutical Group Inc is engaged in China's healthcare sector. As a pharmaceutical manufacturer, the company's portfolio comprises Western pharmaceutical preparations, bulk drugs, traditional Chinese medicines, as well as diagnostic reagents and equipment. Its drug address serious conditions such as gastrointestinal, cardiovascular, anti-infectious, antimicrobial, antineoplastic, hemopoietic system, and other conditions. It distributes its products within domestic markets and to overseas markets. It operates in a single reportable segment which is pharmaceutical manufacturing.

Executives

Xu Guo Xiang	Directors, executives
Tang Yang Gang	Directors, executives
Yang Liang	Secretary Dong
Si Yan Xia	Executives
Zhou Peng	Executives
Huang Yu Xuan	Executives
Huang Hua Min	Supervisors
Yang Dai Hong	Executives
Wang Wu Ping	Executives

Livzon Pharmaceutical Group (SZSE:000513) Headlines

No Headlines